Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients

Xu,Yujin; Wang,Liancong; Zheng,Xiao; Liu,Guan; Wang,Yuezhen; Lai,Xiaojing; Li,Jianqiang

doi:10.3892/mco.2013.72

May-June 2013 Volume 1 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-June 2013 Volume 1 Issue 3

Full Size Image

Article

Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients

Authors:
- Yujin Xu
- Liancong Wang
- Xiao Zheng
- Guan Liu
- Yuezhen Wang
- Xiaojing Lai
- Jianqiang Li
View Affiliations / Copyright

Affiliations: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, P.R. China, Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R.China
Pages: 487-492
|
Published online on: January 24, 2013

https://doi.org/10.3892/mco.2013.72
Expand metrics +

Abstract

The incidence of lung cancer is one of the leading causes of mortality. This study aimed to investigate the prognostic and predictive importance of p53, c‑erbB2 and multidrug resistance proteins (MRP) expression and its correlation with clinicopathological characteristics of patients with non‑small cell lung cancer (NSCLC). Expression of p53, c‑erbB2 and MRP proteins in 152 tumor samples from resected primary NSCLCs was detected by immunohistochemical staining. The correlation of proteins, survival and clinicopathological characteristics was investigated in 152 patients undergoing potentially curative surgery. The positive rates of p53, c‑erbB2 and MRP expression were 53.9 (82/152), 44.1 (67/152) and 43.4% (66/152), respectively. Overall survival rates of patients were markedly correlated with the overexpression of p53, c‑erbB2 and MRP proteins. One, 2- and 3-year survival rates of patients exhibiting a positive expression of these proteins were 72.6, 54.8 and 32.2%, respectively. These rates were lower compared with those of patients with a negative expression of these proteins (92.1, 78.5 and 63.4%) (P=0.02, 0.01 or 0.00, respectively). Results of Cox's regression analysis showed that c‑erbB2 expression and cell differentiation were independent prognostic factors in patients with NSCLC. These findings suggest that the positive expression of p53, c‑erbB2 and MRP proteins is correlated with the survival rates of NSCLC patients. Detection of positive p53, c‑erbB2 and MRP expression may be a useful predictive indicator of prognosis. Positive c‑erbB2 expression is an independent prognostic factor, with a potential to be used as a predictive indicator of chemotherapy efficacy in NSCLC patients.

View Figures

View References

1.	Bunn PA: Future directions in clinical research for lung cancer. Chest. 106:399–407. 1994. View Article : Google Scholar : PubMed/NCBI
2.	Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Mountain CF: Revisions in the international system for staging Lung Cancer. Chest. 111:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
4.	Tsao MS, Aviel-Ronen S, Ding K, et al: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small cell lung cancer. J Clin Oncol. 25:5240–5247. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Bai H, Zhang XY, Ji H, et al: Expression and the clinical significance of p53 and nm23 in non-small cell lung cancers. J Prac Oncol. 19:497–500. 2004.
6.	Ota E, Abe Y, Oshika Y, et al: Expression of the multidrug resistance-associated protein (MRP) gene in non-small cell lung cancer. Br J Cancer. 72:550–554. 1995. View Article : Google Scholar : PubMed/NCBI
7.	Bu H and Pang ZG: Research progress of C-erbB-2 gene in breast cancers. Gene News. 1:122001.
8.	Kristiansen G, Yu Y, Petersen S, et al: Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer. 37:1089–1095. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Turken O, Kunter E, Cermik H, et al: Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC). Neoplasma. 50:257–261. 2003.PubMed/NCBI
10.	Rusch V, Klimstra D, Venkatraman E, et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemo-therapy in locally advanced non-small cell lung cancer. Cancer Res. 55:5038–5042. 1995.PubMed/NCBI
11.	Izquierdo MA, Shoemaker RH, Flens MJ, et al: Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int J Cancer. 65:230–237. 1996. View Article : Google Scholar : PubMed/NCBI
12.	Sengupta S and Harris CC: p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol. 6:44–55. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Huang PY, Liang XM, Lin SX, et al: Correlations analysis among expression of ERCC1, metallothionein p53 and platinum resistance and prognosis in advanced non-small cell lung cancer. Chin J Cancer. 23:845–850. 2004.PubMed/NCBI
14.	Zhang HT: p53 and chemotherapy sensitivity. Foreign Medicine: Oncology. 28:344–347. 2001.
15.	Lee JS, Yoon A, Kalapurakal SK, et al: Expression of p53 onco-protein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol. 13:1893–1903. 1995.PubMed/NCBI
16.	Kwiatkowski DJ, Harpole DH, Godleski J, et al: Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: clinical implications. J Clin Oncol. 16:2468–2477. 1998.PubMed/NCBI
17.	Ebina SM, Mulshine JL, Linnoila RI, et al: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 54:2496–2503. 1994.PubMed/NCBI
18.	Filipits M, Haddad V, Schmid K, et al: Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res. 13:3892–3898. 2007. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Positive expression of p53, c-erbB2 and MRP proteins is correlated with survival rates of NSCLC patients

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles